Sort   by:  
 Page size 
ProteomicsCSF proteomics of aducanumab treated APP-SAA triple knock-in mice
Anti-amyloid β-peptide (Aβ) immunotherapy was developed as treatment for Alzheimer’s disease to reduce and prevent amyloid plaque pathology and its downstream consequences. Efficient amyloid plaque clearance has been proven in clinical trials with Aducanumab, Lecanemab and Donanemab. At least two of...
ORGANISM(S): Mus musculus (Mouse) 
2025-08-25 | PXD061932 | Pride
Cerebrospinal fluid Mouse Diapasef Aducanumab 
ProteomicsCSF and brain proteomics of Trem2-mKate2 KI/wt.APPSAA/SAA.hTfR KI/KI mice
Triggering receptor expressed on myeloid cells 2 (TREM2) is a central regulator of microglial activity and loss-of-function coding variants are major risk factors for late onset Alzheimer’s disease (LOAD). To better understand the molecular and functional changes associated with TREM2 signalling in ...
ORGANISM(S): Mus musculus (Mouse) 
2025-12-08 | PXD065438 | Pride
Alzheimer's disease Csf Mouse Brain Trem2 Antibody treatment 
Sort   by:  
 Page size